App-Quantinova.ai

A phase II study of Foretinib for triple negative metastatic breast cancer: NCIC CTG IND 197

Rayson D - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Foretinib

A phase I clinical trial of entinostat and lapatinib in patients with trastuzumab refractory HER2-positive metastatic breast cancer

Ueno NT - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Breast cancer

Trastuzumab

IMPACT: IMaging PAtients for Cancer drug selecTion Metastatic breast cancer (MBC)

Bensch F - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Dual HER2 blockade of an activating driver HER3 mutation: A proof of principle study in a metastatic breast cancer patient

Bidard F-C - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Trastuzumab

Influence of lifestyle factors and tumor cell dissemination in 632 early breast cancer patients

Aktas B - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Metformin Hydrochloride

Perioperative administration of desmopressin (dDAVP) in breast cancer patients: A phase II dose-escalation study

Weinberg RS - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Desmopressin

Phase Ib dose-escalation study of an Akt inhibitor ipatasertib (Ipat) in combination with docetaxel (Doc) or paclitaxel (Pac) in patients (pts) with metastatic breast cancer (MBC)

Isakoff SJ - San Antonio Breast Cancer Symposium (SABCS) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Ipatasertib

Circulating tumour cell release in the peri-operative setting during curative colorectal cancer surgery

K. Spring - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2015

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

N/A

Classifying circulating, mutation bearing tumor cells from breast cancer patients.

William Strauss - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Methadone hydrochloride

4EVER: Assessment of circulating tumor cells with a novel, filtration-based method, in a phase IIIb multicenter study for postmenopausal, HER2- negative, estrogen receptor-positive, advanced breast cancer patients.

Peter A. Fasching - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Everolimus

Evaluation of risk recurrence in early breast cancer assessed by Oncotype dx and tumor cell dissemination to blood and bone marrow.

Bahriye Aktas - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients (pts) with breast cancer brain metastases (BCBM).

Nancy U. Lin - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

Bevacizumab

Biomarq: A novel approach to automated HER2-analysis of circulating tumor cells (CTCs).

Aurelia Pestka - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

The impact of patient-related factors on the occurrence of febrile neutropenia in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin, and cyclofosfamide (FEC) x6 or FEC x3 followed by docetaxel (D) x3.

Christof Vulsteke - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Adrucil injection

Etirinotecan pegol (EP) target-specific pharmacodynamic (PD) biomarkers measured in circulating tumor cells (CTCs) from patients in the phase III BEACON study in patients with metastatic breast cancer (mBC).

Ute Hoch - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

etirinotecan pegol

Phase Ib study of eribulin (ERB) and cyclophosphamide (CTX) in metastatic breast cancer (MBC).

Thach-Giao Truong - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Cyclophosphamide

Acute and late side effects after intraoperative electron radiotherapy during breast conserving surgery of breast cancer.

Christiane Matuschek - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

carisoprodol

An adaptive randomized phase II trial to determine pathologic complete response with the addition of carboplatin with and without ABT-888 to standard chemotherapy in the neoadjuvant treatment of triple-negative breast cancer.

Tiffany P. Avery - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Cyclophosphamide

Imaging techniques in pancreatic cancer screening: Preliminary results from the PanGen-FAM registry.

Carmen Guillen-Ponce - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF inhibitors (VEGFi).

Kurt A. Jaeckle - American Society of Clinical Oncology (ASCO) , 2013

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glioblastoma

Temozolomide

Filters

1671 Abstracts